Kaiser Permanente Washington Health Research Institute, Seattle.
Center for Behavioral Cardiovascular Health, Columbia University Irving Medical Center, New York, New York.
JAMA. 2024 Jul 9;332(2):141-152. doi: 10.1001/jama.2024.5756.
IMPORTANCE: Approximately 9% of US adults experience major depression each year, with a lifetime prevalence of approximately 17% for men and 30% for women. OBSERVATIONS: Major depression is defined by depressed mood, loss of interest in activities, and associated psychological and somatic symptoms lasting at least 2 weeks. Evaluation should include structured assessment of severity as well as risk of self-harm, suspected bipolar disorder, psychotic symptoms, substance use, and co-occurring anxiety disorder. First-line treatments include specific psychotherapies and antidepressant medications. A network meta-analysis of randomized clinical trials reported cognitive therapy, behavioral activation, problem-solving therapy, interpersonal therapy, brief psychodynamic therapy, and mindfulness-based psychotherapy all had at least medium-sized effects in symptom improvement over usual care without psychotherapy (standardized mean difference [SMD] ranging from 0.50 [95% CI, 0.20-0.81] to 0.73 [95% CI, 0.52-0.95]). A network meta-analysis of randomized clinical trials reported 21 antidepressant medications all had small- to medium-sized effects in symptom improvement over placebo (SMD ranging from 0.23 [95% CI, 0.19-0.28] for fluoxetine to 0.48 [95% CI, 0.41-0.55] for amitriptyline). Psychotherapy combined with antidepressant medication may be preferred, especially for more severe or chronic depression. A network meta-analysis of randomized clinical trials reported greater symptom improvement with combined treatment than with psychotherapy alone (SMD, 0.30 [95% CI, 0.14-0.45]) or medication alone (SMD, 0.33 [95% CI, 0.20-0.47]). When initial antidepressant medication is not effective, second-line medication treatment includes changing antidepressant medication, adding a second antidepressant, or augmenting with a nonantidepressant medication, which have approximately equal likelihood of success based on a network meta-analysis. Collaborative care programs, including systematic follow-up and outcome assessment, improve treatment effectiveness, with 1 meta-analysis reporting significantly greater symptom improvement compared with usual care (SMD, 0.42 [95% CI, 0.23-0.61]). CONCLUSIONS AND RELEVANCE: Effective first-line depression treatments include specific forms of psychotherapy and more than 20 antidepressant medications. Close monitoring significantly improves the likelihood of treatment success.
重要性: 大约 9%的美国成年人每年都会经历重度抑郁症,男性终身患病率约为 17%,女性终身患病率约为 30%。
观察结果: 重度抑郁症的定义是情绪低落、对活动失去兴趣以及持续至少 2 周的相关心理和躯体症状。评估应包括严重程度的结构化评估以及自伤风险、疑似双相情感障碍、精神病症状、物质使用和同时存在的焦虑症的评估。一线治疗包括特定的心理治疗和抗抑郁药物。一项随机临床试验的网络荟萃分析报告称,认知疗法、行为激活、解决问题疗法、人际疗法、简短心理动力学疗法和基于正念的心理疗法在改善症状方面均优于不接受心理治疗的常规护理(标准化均数差[SMD]范围为 0.50[95%CI,0.20-0.81]至 0.73[95%CI,0.52-0.95])。一项随机临床试验的网络荟萃分析报告称,21 种抗抑郁药物在改善症状方面均优于安慰剂(氟西汀的 SMD 范围为 0.23[95%CI,0.19-0.28],阿米替林的 SMD 范围为 0.48[95%CI,0.41-0.55])。抗抑郁药物联合心理治疗可能是首选,尤其是对于更严重或慢性的抑郁症。一项随机临床试验的网络荟萃分析报告称,联合治疗比单独心理治疗(SMD,0.30[95%CI,0.14-0.45])或单独药物治疗(SMD,0.33[95%CI,0.20-0.47])更能改善症状。如果初始抗抑郁药物无效,二线药物治疗包括更换抗抑郁药物、添加第二种抗抑郁药物或用非抗抑郁药物增效,基于网络荟萃分析,这三种治疗方法的成功率大致相同。包括系统随访和结果评估的协作式护理计划可提高治疗效果,1 项荟萃分析报告称,与常规护理相比,该计划显著改善了症状(SMD,0.42[95%CI,0.23-0.61])。
结论和相关性: 有效的一线治疗方法包括特定形式的心理治疗和 20 多种抗抑郁药物。密切监测显著提高了治疗成功的可能性。
JAMA. 2024-7-9
Cochrane Database Syst Rev. 2018-5-14
Cochrane Database Syst Rev. 2019-5-20
Cochrane Database Syst Rev. 2014-11-30
Ont Health Technol Assess Ser. 2019-2-19
Cochrane Database Syst Rev. 2020-10-13
Cochrane Database Syst Rev. 2012-11-14
Cochrane Database Syst Rev. 2018-3-4
Cochrane Database Syst Rev. 2021-5-24
Am J Lifestyle Med. 2025-8-29
Eur J Cardiothorac Surg. 2025-8-2